Solid Biosciences (SLDB) FCF Margin (2021 - 2022)
Solid Biosciences (SLDB) reported FCF Margin of 275.8% for Q2 2022, up 21040.0% on a YoY basis from N/an in Q2 2021, and up 80.61% sequentially from 1422.03% in Q1 2022.
Solid Biosciences (SLDB) FCF Margin (2021 - 2022) Analysis & Trends
Solid Biosciences (SLDB) has 2 years of FCF Margin data on file, last reported at 275.8% in Q2 2022.
- For the quarter ending Q2 2022, FCF Margin rose 21040.0% year-over-year to 275.8%; the trailing twelve-month figure through Mar 2023 stood at 1615.03% (down 92816.0% YoY), and the FY2022 full-year result was 1217.0%, down 64528.0% from the prior year.
- FCF Margin advanced to 275.8% in Q2 2022, from 1422.03% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 275.8% in Q2 2022 to a low of 1422.03% in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -275.80% |
| Mar 31, 2022 | -1,422.03% |
| Dec 31, 2021 | -654.19% |
| Sep 30, 2021 | -519.79% |
| Jun 30, 2021 | -486.20% |
| Mar 31, 2021 | -640.96% |